Skip to content

The use of Telosma pallida fruits in leucoderma

A non-randomized, observational clinical study on formulation containing aqueous juice of Telosma pallida (Roxb.) Craib. Fruit for the treatment of white patches on the skin (leucoderma) - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/12/078711
Enrollment
30
Registered
2024-12-30
Start date
Unknown
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

Intervention1: Juice of Telosma pallida fruits: Lotion or any other suitable formulation containing aqueous juice of fruits of Telosma pallida will be provided to the patients. Frequency - daily Tota

Sponsors

Dharmsinh Desai University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Male or female patient with confirmed leucoderma due to genetic or non-genetic reason can be included in the study.

Exclusion criteria

Exclusion criteria: Female patients having pregnancy, breast feeding or post-delivery period. Patients having evidence of extensive disease or any other treatment is continue. Patients having patches or white spots due to chemical or burning hazard.

Design outcomes

Primary

MeasureTime frame
Skin color will be changed towards normal from hyperpigmentation. This will be evaluated using the method given by Geel et al. (2020). 1. confetti-like depigmentation 2. Koebner phenomenon 3. hypochromic areas/borders Timepoint: Time-point is 4 weeks.

Secondary

MeasureTime frame
Size of the white patches or number of white patches will be reduced. The size of the white patches may be measured by putting a transparent plastic sheet on the skin & draw the area of the patch using pointed marker pen. The scoring method to assess the effect of the treatment will be adopted. Timepoint: Time points will be, measurement at the end of the 1st 2nd 3rd & 4th week of the treatment.

Countries

India

Contacts

Public ContactDr Tejal G Soni

Faculty of Pharmacy, Dharmsinh Desai University

tejalsoni.ph@ddu.ac.in9601904294

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026